ICU Medical (NASDAQ:ICUI) Raised to "Buy" at StockNews.com

StockNews.com upgraded shares of ICU Medical (NASDAQ:ICUI - Free Report) from a hold rating to a buy rating in a report published on Tuesday morning.

Other research analysts have also recently issued reports about the stock. Jefferies Financial Group raised shares of ICU Medical from a "hold" rating to a "buy" rating and set a $200.00 target price for the company in a report on Wednesday, December 11th. Raymond James set a $97.00 target price on ICU Medical in a research report on Wednesday, March 12th. One investment analyst has rated the stock with a hold rating, three have assigned a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, ICU Medical currently has an average rating of "Buy" and an average price target of $168.67.

ICU Medical Price Performance

Shares of NASDAQ ICUI traded down $1.03 during trading on Tuesday, hitting $147.07. 256,395 shares of the company were exchanged, compared to its average volume of 255,872. The firm's fifty day moving average price is $156.22 and its 200 day moving average price is $164.53. The company has a debt-to-equity ratio of 0.75, a current ratio of 2.29 and a quick ratio of 1.03. The company has a market cap of $3.61 billion, a price-to-earnings ratio of -31.97 and a beta of 0.73. ICU Medical has a 1 year low of $93.36 and a 1 year high of $196.26.

Remove Ads

Insider Buying and Selling

In other ICU Medical news, CEO Vivek Jain sold 1,373 shares of the company's stock in a transaction dated Thursday, January 2nd. The shares were sold at an average price of $155.48, for a total value of $213,474.04. Following the transaction, the chief executive officer now directly owns 104,593 shares in the company, valued at approximately $16,262,119.64. This represents a 1.30 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Insiders own 6.70% of the company's stock.

Hedge Funds Weigh In On ICU Medical

Several institutional investors and hedge funds have recently modified their holdings of the company. Barclays PLC boosted its holdings in shares of ICU Medical by 15.6% during the third quarter. Barclays PLC now owns 59,207 shares of the medical instruments supplier's stock worth $10,790,000 after purchasing an additional 8,010 shares during the last quarter. LMR Partners LLP acquired a new stake in ICU Medical in the 3rd quarter worth about $3,884,000. Principal Financial Group Inc. grew its holdings in ICU Medical by 24.6% in the 3rd quarter. Principal Financial Group Inc. now owns 126,937 shares of the medical instruments supplier's stock valued at $23,130,000 after buying an additional 25,031 shares during the period. MetLife Investment Management LLC boosted its position in shares of ICU Medical by 129.1% in the third quarter. MetLife Investment Management LLC now owns 12,389 shares of the medical instruments supplier's stock worth $2,258,000 after acquiring an additional 6,981 shares during the last quarter. Finally, Jennison Associates LLC acquired a new stake in shares of ICU Medical in the fourth quarter worth approximately $556,000. Hedge funds and other institutional investors own 96.10% of the company's stock.

About ICU Medical

ICU Medical, Inc, together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; and ClearGuard, SwabCap, and SwabTip disinfection caps.